32
Participants
Start Date
August 31, 2006
Primary Completion Date
August 31, 2008
Study Completion Date
July 31, 2011
Bevacizumab
Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
Erlotinib
Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
Gemcitabine
Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Genentech, Inc.
INDUSTRY
Beth Israel Deaconess Medical Center
OTHER
Dana-Farber Cancer Institute
OTHER
Massachusetts General Hospital
OTHER